|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:SPTLC3-PPAP2A (FusionGDB2 ID:85593) |
Fusion Gene Summary for SPTLC3-PPAP2A |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SPTLC3-PPAP2A | Fusion gene ID: 85593 | Hgene | Tgene | Gene symbol | SPTLC3 | PPAP2A | Gene ID | 55304 | 8611 |
| Gene name | serine palmitoyltransferase long chain base subunit 3 | phospholipid phosphatase 1 | |
| Synonyms | C20orf38|LCB 3|LCB2B|LCB3|SPT 3|SPT3|SPTLC2L|dJ718P11|dJ718P11.1|hLCB2b | LLP1a|LPP1|PAP-2a|PAP2|PPAP2A | |
| Cytomap | 20p12.1 | 5q11.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine palmitoyltransferase 3long chain base biosynthesis protein 2blong chain base biosynthesis protein 3serine palmitoyltransferase, long chain base subunit 2-like (aminotransferase 2)serine-palmitoyl-CoA transferase 3 | phospholipid phosphatase 1lipid phosphate phosphohydrolase 1aphosphatidate phosphohydrolase type 2aphosphatidic acid phosphatase 2aphosphatidic acid phosphatase type 2Aphosphatidic acid phosphohydrolase type 2atype-2 phosphatidic acid phosphatase al | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | . | |
| Ensembl transtripts involved in fusion gene | ENST00000399002, ENST00000378194, ENST00000476791, | ENST00000264775, ENST00000307259, ENST00000515132, | |
| Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 10 X 5 X 6=300 |
| # samples | 3 | 10 | |
| ** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(10/300*10)=-1.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: SPTLC3 [Title/Abstract] AND PPAP2A [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | SPTLC3(13090864)-PPAP2A(54737736), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | SPTLC3 | GO:0046520 | sphingoid biosynthetic process | 19648650 |
| Tgene | PPAP2A | GO:0006644 | phospholipid metabolic process | 9305923|9705349|15461590 |
| Tgene | PPAP2A | GO:0006670 | sphingosine metabolic process | 9705349 |
| Tgene | PPAP2A | GO:0006672 | ceramide metabolic process | 9305923|9705349 |
| Tgene | PPAP2A | GO:0046839 | phospholipid dephosphorylation | 9305923|9705349|15461590|16464866 |
| Fusion gene breakpoints across SPTLC3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across PPAP2A (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | OV | TCGA-25-1329-01A | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| ChimerDB4 | OV | TCGA-25-1329-01A | SPTLC3 | chr20 | 13090864 | - | PPAP2A | chr5 | 54737736 | - |
Top |
Fusion Gene ORF analysis for SPTLC3-PPAP2A |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000399002 | ENST00000264775 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| In-frame | ENST00000399002 | ENST00000307259 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| 5CDS-5UTR | ENST00000399002 | ENST00000515132 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| In-frame | ENST00000378194 | ENST00000264775 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| In-frame | ENST00000378194 | ENST00000307259 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| 5CDS-5UTR | ENST00000378194 | ENST00000515132 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| intron-3CDS | ENST00000476791 | ENST00000264775 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| intron-3CDS | ENST00000476791 | ENST00000307259 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| intron-5UTR | ENST00000476791 | ENST00000515132 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000399002 | SPTLC3 | chr20 | 13090864 | + | ENST00000264775 | PPAP2A | chr5 | 54737736 | - | 1922 | 1206 | 274 | 1569 | 431 |
| ENST00000399002 | SPTLC3 | chr20 | 13090864 | + | ENST00000307259 | PPAP2A | chr5 | 54737736 | - | 1891 | 1206 | 274 | 1569 | 431 |
| ENST00000378194 | SPTLC3 | chr20 | 13090864 | + | ENST00000264775 | PPAP2A | chr5 | 54737736 | - | 1742 | 1026 | 94 | 1389 | 431 |
| ENST00000378194 | SPTLC3 | chr20 | 13090864 | + | ENST00000307259 | PPAP2A | chr5 | 54737736 | - | 1711 | 1026 | 94 | 1389 | 431 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000399002 | ENST00000264775 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - | 0.000671586 | 0.9993285 |
| ENST00000399002 | ENST00000307259 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - | 0.000714917 | 0.99928516 |
| ENST00000378194 | ENST00000264775 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - | 0.000776612 | 0.99922335 |
| ENST00000378194 | ENST00000307259 | SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737736 | - | 0.000851304 | 0.9991487 |
Top |
Fusion Genomic Features for SPTLC3-PPAP2A |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737733 | - | 0.9999728 | 2.72E-05 |
| SPTLC3 | chr20 | 13090864 | + | PPAP2A | chr5 | 54737733 | - | 0.9999728 | 2.72E-05 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for SPTLC3-PPAP2A |
| Go to FGviewer for the breakpoints of chr20:13090864-chr5:54737736 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | . |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | SPTLC3 | chr20:13090864 | chr5:54737736 | ENST00000399002 | + | 7 | 12 | 59_79 | 310.6666666666667 | 553.0 | Transmembrane | Helical |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 168_171 | 164.66666666666666 | 286.0 | Region | Phosphatase sequence motif II | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 216_227 | 164.66666666666666 | 286.0 | Region | Phosphatase sequence motif III | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 168_171 | 163.66666666666666 | 285.0 | Region | Phosphatase sequence motif II | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 216_227 | 163.66666666666666 | 285.0 | Region | Phosphatase sequence motif III | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 186_199 | 164.66666666666666 | 286.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 221_229 | 164.66666666666666 | 286.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 251_284 | 164.66666666666666 | 286.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 186_199 | 163.66666666666666 | 285.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 221_229 | 163.66666666666666 | 285.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 251_284 | 163.66666666666666 | 285.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 165_185 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 200_220 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 230_250 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 165_185 | 163.66666666666666 | 285.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 200_220 | 163.66666666666666 | 285.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 230_250 | 163.66666666666666 | 285.0 | Transmembrane | Helical |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 5_7 | 164.66666666666666 | 286.0 | Motif | PDZ-binding%3B involved in localization to the apical cell membrane | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 5_7 | 163.66666666666666 | 285.0 | Motif | PDZ-binding%3B involved in localization to the apical cell membrane | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 120_128 | 164.66666666666666 | 286.0 | Region | Phosphatase sequence motif I | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 120_128 | 163.66666666666666 | 285.0 | Region | Phosphatase sequence motif I | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 116_164 | 164.66666666666666 | 286.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 1_6 | 164.66666666666666 | 286.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 28_53 | 164.66666666666666 | 286.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 75_94 | 164.66666666666666 | 286.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 116_164 | 163.66666666666666 | 285.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 1_6 | 163.66666666666666 | 285.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 28_53 | 163.66666666666666 | 285.0 | Topological domain | Extracellular | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 75_94 | 163.66666666666666 | 285.0 | Topological domain | Cytoplasmic | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 54_74 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 7_27 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000264775 | 2 | 6 | 95_115 | 164.66666666666666 | 286.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 54_74 | 163.66666666666666 | 285.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 7_27 | 163.66666666666666 | 285.0 | Transmembrane | Helical | |
| Tgene | PPAP2A | chr20:13090864 | chr5:54737736 | ENST00000307259 | 2 | 6 | 95_115 | 163.66666666666666 | 285.0 | Transmembrane | Helical |
Top |
Fusion Gene Sequence for SPTLC3-PPAP2A |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000399002_ENST00000264775_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(transcript)=1922nt_BP=1206nt GGACAATCTCCTTTACAGTTTCGGAAGCAGGTTTGTTGCCATGGAGTTCACATTTTGACGGGAGTTGAGAAGTATAAAGGTAACCATTTG TTTTAGTTTCAACGATCTGACAAAAAGATAGGCTGTTGCTCTTCTTCTGGAAAAGCCTGATTGGTAAGATTCCTTTAAGGGCTCAGCCCC AAAGAGCTTTATCCCATCCCCTCGCAGACTGAAAACTAAAGCCTGCAGAGACCTCTGAAGGAAAACCTGTCCCGGGCTCTGTCACTTCAC ACCCATGGCTAACCCTGGAGGTGGTGCTGTTTGCAACGGGAAACTTCACAATCACAAGAAACAGAGCAATGGCTCACAAAGCAGAAACTG CACAAAGAATGGAATAGTGAAGGAAGCCCAGCAAAATGGGAAGCCACATTTTTATGATAAGCTCATTGTTGAATCGTTTGAGGAAGCACC CCTTCATGTTATGGTTTTCACTTACATGGGATATGGAATTGGAACCCTGTTTGGCTATCTCAGAGACTTTTTAAGAAACTGGGGAATAGA AAAATGCAACGCAGCTGTGGAAAGAAAAGAACAAAAAGATTTTGTGCCACTGTATCAAGACTTTGAAAATTTTTATACAAGAAACCTTTA CATGCGAATCAGAGACAACTGGAACCGGCCCATCTGCAGTGCCCCAGGGCCTCTGTTTGATTTGATGGAGAGGGTATCAGACGACTATAA CTGGACGTTTAGGTTTACTGGAAGAGTCATCAAAGATGTCATCAACATGGGCTCCTATAACTTCCTTGGTCTTGCAGCCAAGTATGATGA GTCTATGAGGACAATAAAGGATGTTTTAGAGGTGTATGGCACAGGCGTGGCCAGCACCAGGCATGAAATGGGCACCTTGGATAAGCACAA GGAGTTGGAGGACCTTGTGGCTAAGTTCCTGAATGTGGAAGCAGCTATGGTCTTTGGGATGGGATTCGCAACTAACTCAATGAATATCCC AGCATTAGTTGGAAAGGGATGCCTCATTTTAAGTGATGAGTTAAACCACACATCGCTTGTGCTTGGGGCCCGACTCTCAGGTGCAACCAT AAGAATCTTCAAACACAACAACACACAAAGCCTAGAGAAGCTCCTGAGAGATGCTGTCATCTATGGCCAGCCTCGAACCCGCAGAGCTTG GAAAAAGATTCTCATCCTGGTGGAGGGTGTCTACAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGTACTGCATGCTGTTTGT GGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAGACTCTTACGCCCCACACTGCAATTTGGTCTTGTTGCCGTATCCATTTA TGTGGGCCTTTCTCGAGTTTCTGATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGGGAGCTCTGGTTGCAATATTAGT TGCTGTATATGTATCGGATTTCTTCAAAGAAAGAACTTCTTTTAAAGAAAGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACC AACAACTGGGAATCACTATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTGAAGCTGGCCTGTTTTCTAAAGGAAAATG ATTGCCACAAGGCAAGAGGATGCATCTTTCTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGCTATGCCTCTTGGATGCACACTT TGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTAAAAAAACTCCAAGCCTTCCACCAAAACAGTGCCC CACCTGTATACATTTTTATTAAAAAAATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTAAATA >In-frame_ENST00000399002_ENST00000264775_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(amino acids)=431AA_start in transcript=274_stop in transcript=1569 MANPGGGAVCNGKLHNHKKQSNGSQSRNCTKNGIVKEAQQNGKPHFYDKLIVESFEEAPLHVMVFTYMGYGIGTLFGYLRDFLRNWGIEK CNAAVERKEQKDFVPLYQDFENFYTRNLYMRIRDNWNRPICSAPGPLFDLMERVSDDYNWTFRFTGRVIKDVINMGSYNFLGLAAKYDES MRTIKDVLEVYGTGVASTRHEMGTLDKHKELEDLVAKFLNVEAAMVFGMGFATNSMNIPALVGKGCLILSDELNHTSLVLGARLSGATIR IFKHNNTQSLEKLLRDAVIYGQPRTRRAWKKILILVEGVYRLSFYSGHSSFSMYCMLFVALYLQARMKGDWARLLRPTLQFGLVAVSIYV -------------------------------------------------------------- >In-frame_ENST00000399002_ENST00000307259_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(transcript)=1891nt_BP=1206nt GGACAATCTCCTTTACAGTTTCGGAAGCAGGTTTGTTGCCATGGAGTTCACATTTTGACGGGAGTTGAGAAGTATAAAGGTAACCATTTG TTTTAGTTTCAACGATCTGACAAAAAGATAGGCTGTTGCTCTTCTTCTGGAAAAGCCTGATTGGTAAGATTCCTTTAAGGGCTCAGCCCC AAAGAGCTTTATCCCATCCCCTCGCAGACTGAAAACTAAAGCCTGCAGAGACCTCTGAAGGAAAACCTGTCCCGGGCTCTGTCACTTCAC ACCCATGGCTAACCCTGGAGGTGGTGCTGTTTGCAACGGGAAACTTCACAATCACAAGAAACAGAGCAATGGCTCACAAAGCAGAAACTG CACAAAGAATGGAATAGTGAAGGAAGCCCAGCAAAATGGGAAGCCACATTTTTATGATAAGCTCATTGTTGAATCGTTTGAGGAAGCACC CCTTCATGTTATGGTTTTCACTTACATGGGATATGGAATTGGAACCCTGTTTGGCTATCTCAGAGACTTTTTAAGAAACTGGGGAATAGA AAAATGCAACGCAGCTGTGGAAAGAAAAGAACAAAAAGATTTTGTGCCACTGTATCAAGACTTTGAAAATTTTTATACAAGAAACCTTTA CATGCGAATCAGAGACAACTGGAACCGGCCCATCTGCAGTGCCCCAGGGCCTCTGTTTGATTTGATGGAGAGGGTATCAGACGACTATAA CTGGACGTTTAGGTTTACTGGAAGAGTCATCAAAGATGTCATCAACATGGGCTCCTATAACTTCCTTGGTCTTGCAGCCAAGTATGATGA GTCTATGAGGACAATAAAGGATGTTTTAGAGGTGTATGGCACAGGCGTGGCCAGCACCAGGCATGAAATGGGCACCTTGGATAAGCACAA GGAGTTGGAGGACCTTGTGGCTAAGTTCCTGAATGTGGAAGCAGCTATGGTCTTTGGGATGGGATTCGCAACTAACTCAATGAATATCCC AGCATTAGTTGGAAAGGGATGCCTCATTTTAAGTGATGAGTTAAACCACACATCGCTTGTGCTTGGGGCCCGACTCTCAGGTGCAACCAT AAGAATCTTCAAACACAACAACACACAAAGCCTAGAGAAGCTCCTGAGAGATGCTGTCATCTATGGCCAGCCTCGAACCCGCAGAGCTTG GAAAAAGATTCTCATCCTGGTGGAGGGTGTCTACAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGTACTGCATGCTGTTTGT GGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAGACTCTTACGCCCCACACTGCAATTTGGTCTTGTTGCCGTATCCATTTA TGTGGGCCTTTCTCGAGTTTCTGATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGGGAGCTCTGGTTGCAATATTAGT TGCTGTATATGTATCGGATTTCTTCAAAGAAAGAACTTCTTTTAAAGAAAGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACC AACAACTGGGAATCACTATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTGAAGCTGGCCTGTTTTCTAAAGGAAAATG ATTGCCACAAGGCAAGAGGATGCATCTTTCTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGCTATGCCTCTTGGATGCACACTT TGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTAAAAAAACTCCAAGCCTTCCACCAAAACAGTGCCC CACCTGTATACATTTTTATTAAAAAAATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTAAATA >In-frame_ENST00000399002_ENST00000307259_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(amino acids)=431AA_start in transcript=274_stop in transcript=1569 MANPGGGAVCNGKLHNHKKQSNGSQSRNCTKNGIVKEAQQNGKPHFYDKLIVESFEEAPLHVMVFTYMGYGIGTLFGYLRDFLRNWGIEK CNAAVERKEQKDFVPLYQDFENFYTRNLYMRIRDNWNRPICSAPGPLFDLMERVSDDYNWTFRFTGRVIKDVINMGSYNFLGLAAKYDES MRTIKDVLEVYGTGVASTRHEMGTLDKHKELEDLVAKFLNVEAAMVFGMGFATNSMNIPALVGKGCLILSDELNHTSLVLGARLSGATIR IFKHNNTQSLEKLLRDAVIYGQPRTRRAWKKILILVEGVYRLSFYSGHSSFSMYCMLFVALYLQARMKGDWARLLRPTLQFGLVAVSIYV -------------------------------------------------------------- >In-frame_ENST00000378194_ENST00000264775_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(transcript)=1742nt_BP=1026nt AAAGAGCTTTATCCCATCCCCTCGCAGACTGAAAACTAAAGCCTGCAGAGACCTCTGAAGGAAAACCTGTCCCGGGCTCTGTCACTTCAC ACCCATGGCTAACCCTGGAGGTGGTGCTGTTTGCAACGGGAAACTTCACAATCACAAGAAACAGAGCAATGGCTCACAAAGCAGAAACTG CACAAAGAATGGAATAGTGAAGGAAGCCCAGCAAAATGGGAAGCCACATTTTTATGATAAGCTCATTGTTGAATCGTTTGAGGAAGCACC CCTTCATGTTATGGTTTTCACTTACATGGGATATGGAATTGGAACCCTGTTTGGCTATCTCAGAGACTTTTTAAGAAACTGGGGAATAGA AAAATGCAACGCAGCTGTGGAAAGAAAAGAACAAAAAGATTTTGTGCCACTGTATCAAGACTTTGAAAATTTTTATACAAGAAACCTTTA CATGCGAATCAGAGACAACTGGAACCGGCCCATCTGCAGTGCCCCAGGGCCTCTGTTTGATTTGATGGAGAGGGTATCAGACGACTATAA CTGGACGTTTAGGTTTACTGGAAGAGTCATCAAAGATGTCATCAACATGGGCTCCTATAACTTCCTTGGTCTTGCAGCCAAGTATGATGA GTCTATGAGGACAATAAAGGATGTTTTAGAGGTGTATGGCACAGGCGTGGCCAGCACCAGGCATGAAATGGGCACCTTGGATAAGCACAA GGAGTTGGAGGACCTTGTGGCTAAGTTCCTGAATGTGGAAGCAGCTATGGTCTTTGGGATGGGATTCGCAACTAACTCAATGAATATCCC AGCATTAGTTGGAAAGGGATGCCTCATTTTAAGTGATGAGTTAAACCACACATCGCTTGTGCTTGGGGCCCGACTCTCAGGTGCAACCAT AAGAATCTTCAAACACAACAACACACAAAGCCTAGAGAAGCTCCTGAGAGATGCTGTCATCTATGGCCAGCCTCGAACCCGCAGAGCTTG GAAAAAGATTCTCATCCTGGTGGAGGGTGTCTACAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGTACTGCATGCTGTTTGT GGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAGACTCTTACGCCCCACACTGCAATTTGGTCTTGTTGCCGTATCCATTTA TGTGGGCCTTTCTCGAGTTTCTGATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGGGAGCTCTGGTTGCAATATTAGT TGCTGTATATGTATCGGATTTCTTCAAAGAAAGAACTTCTTTTAAAGAAAGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACC AACAACTGGGAATCACTATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTGAAGCTGGCCTGTTTTCTAAAGGAAAATG ATTGCCACAAGGCAAGAGGATGCATCTTTCTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGCTATGCCTCTTGGATGCACACTT TGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTAAAAAAACTCCAAGCCTTCCACCAAAACAGTGCCC CACCTGTATACATTTTTATTAAAAAAATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTAAATA >In-frame_ENST00000378194_ENST00000264775_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(amino acids)=431AA_start in transcript=94_stop in transcript=1389 MANPGGGAVCNGKLHNHKKQSNGSQSRNCTKNGIVKEAQQNGKPHFYDKLIVESFEEAPLHVMVFTYMGYGIGTLFGYLRDFLRNWGIEK CNAAVERKEQKDFVPLYQDFENFYTRNLYMRIRDNWNRPICSAPGPLFDLMERVSDDYNWTFRFTGRVIKDVINMGSYNFLGLAAKYDES MRTIKDVLEVYGTGVASTRHEMGTLDKHKELEDLVAKFLNVEAAMVFGMGFATNSMNIPALVGKGCLILSDELNHTSLVLGARLSGATIR IFKHNNTQSLEKLLRDAVIYGQPRTRRAWKKILILVEGVYRLSFYSGHSSFSMYCMLFVALYLQARMKGDWARLLRPTLQFGLVAVSIYV -------------------------------------------------------------- >In-frame_ENST00000378194_ENST00000307259_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(transcript)=1711nt_BP=1026nt AAAGAGCTTTATCCCATCCCCTCGCAGACTGAAAACTAAAGCCTGCAGAGACCTCTGAAGGAAAACCTGTCCCGGGCTCTGTCACTTCAC ACCCATGGCTAACCCTGGAGGTGGTGCTGTTTGCAACGGGAAACTTCACAATCACAAGAAACAGAGCAATGGCTCACAAAGCAGAAACTG CACAAAGAATGGAATAGTGAAGGAAGCCCAGCAAAATGGGAAGCCACATTTTTATGATAAGCTCATTGTTGAATCGTTTGAGGAAGCACC CCTTCATGTTATGGTTTTCACTTACATGGGATATGGAATTGGAACCCTGTTTGGCTATCTCAGAGACTTTTTAAGAAACTGGGGAATAGA AAAATGCAACGCAGCTGTGGAAAGAAAAGAACAAAAAGATTTTGTGCCACTGTATCAAGACTTTGAAAATTTTTATACAAGAAACCTTTA CATGCGAATCAGAGACAACTGGAACCGGCCCATCTGCAGTGCCCCAGGGCCTCTGTTTGATTTGATGGAGAGGGTATCAGACGACTATAA CTGGACGTTTAGGTTTACTGGAAGAGTCATCAAAGATGTCATCAACATGGGCTCCTATAACTTCCTTGGTCTTGCAGCCAAGTATGATGA GTCTATGAGGACAATAAAGGATGTTTTAGAGGTGTATGGCACAGGCGTGGCCAGCACCAGGCATGAAATGGGCACCTTGGATAAGCACAA GGAGTTGGAGGACCTTGTGGCTAAGTTCCTGAATGTGGAAGCAGCTATGGTCTTTGGGATGGGATTCGCAACTAACTCAATGAATATCCC AGCATTAGTTGGAAAGGGATGCCTCATTTTAAGTGATGAGTTAAACCACACATCGCTTGTGCTTGGGGCCCGACTCTCAGGTGCAACCAT AAGAATCTTCAAACACAACAACACACAAAGCCTAGAGAAGCTCCTGAGAGATGCTGTCATCTATGGCCAGCCTCGAACCCGCAGAGCTTG GAAAAAGATTCTCATCCTGGTGGAGGGTGTCTACAGGTTGTCCTTCTATTCAGGCCACTCTTCGTTTTCCATGTACTGCATGCTGTTTGT GGCACTTTATCTTCAAGCCAGGATGAAGGGAGACTGGGCAAGACTCTTACGCCCCACACTGCAATTTGGTCTTGTTGCCGTATCCATTTA TGTGGGCCTTTCTCGAGTTTCTGATTATAAACACCACTGGAGCGATGTGTTGACTGGACTCATTCAGGGAGCTCTGGTTGCAATATTAGT TGCTGTATATGTATCGGATTTCTTCAAAGAAAGAACTTCTTTTAAAGAAAGAAAAGAGGAGGACTCTCATACAACTCTGCATGAAACACC AACAACTGGGAATCACTATCCGAGCAATCACCAGCCTTGAAAGGCAGCAGGGTGCCCAGGTGAAGCTGGCCTGTTTTCTAAAGGAAAATG ATTGCCACAAGGCAAGAGGATGCATCTTTCTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGCTATGCCTCTTGGATGCACACTT TGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTAAAAAAACTCCAAGCCTTCCACCAAAACAGTGCCC CACCTGTATACATTTTTATTAAAAAAATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTAAATA >In-frame_ENST00000378194_ENST00000307259_TCGA-25-1329-01A_SPTLC3_chr20_13090864_+_PPAP2A_chr5_54737736_length(amino acids)=431AA_start in transcript=94_stop in transcript=1389 MANPGGGAVCNGKLHNHKKQSNGSQSRNCTKNGIVKEAQQNGKPHFYDKLIVESFEEAPLHVMVFTYMGYGIGTLFGYLRDFLRNWGIEK CNAAVERKEQKDFVPLYQDFENFYTRNLYMRIRDNWNRPICSAPGPLFDLMERVSDDYNWTFRFTGRVIKDVINMGSYNFLGLAAKYDES MRTIKDVLEVYGTGVASTRHEMGTLDKHKELEDLVAKFLNVEAAMVFGMGFATNSMNIPALVGKGCLILSDELNHTSLVLGARLSGATIR IFKHNNTQSLEKLLRDAVIYGQPRTRRAWKKILILVEGVYRLSFYSGHSSFSMYCMLFVALYLQARMKGDWARLLRPTLQFGLVAVSIYV -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for SPTLC3-PPAP2A |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for SPTLC3-PPAP2A |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for SPTLC3-PPAP2A |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies